Clinical Cancer Research Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, A. O.
Right arrow Articles by Hamilton, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, A. O.
Right arrow Articles by Hamilton, S. R.
Clinical Cancer Research Vol. 11, 8281-8287, December 1, 2005
© 2005 American Association for Cancer Research


Human Cancer Biology

Differing DNA Methylation Patterns and Gene Mutation Frequencies in Colorectal Carcinomas from Middle Eastern Countries

Annie O. Chan1,12, Amr S. Soliman2,5, Qing Zhang2,3, Asif Rashid1, Ahmed Bedeir1, P. Scott Houlihan1, Nadia Mokhtar6, Nidal Al-Masri8, Ugur Ozbek10, Rami Yaghan9, Ayten Kandilci10,11, Sherif Omar7, Yersu Kapran10, Ferhunde Dizdaroglu11, Melissa L. Bondy2,3, Christopher I. Amos2,3, Jean-Pierre Issa4, Bernard Levin3 and Stanley R. Hamilton1

Authors' Affiliations: 1 Department of Pathology, Division of Pathology and Laboratory Medicine; 2 Department of Epidemiology, 3 Division of Cancer Prevention; 4 Department of Leukemia, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 5 Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan; Departments of 6 Pathology and 7 Surgical Oncology, The National Cancer Institute of Cairo University, Cairo, Egypt; Departments of 8 Pathology and 9 Surgery, Jordan University for Science and Technology, Irbid, Jordan; 10 Department of Genetics, Institute for Experimental Medicine; 11 Department of Pathology, Faculty of Medicine, Istanbul University, Istanbul, Turkey; and 12 Department of Medicine, The University of Hong Kong, Hong Kong, People's Republic of China

Requests for reprints: Stanley R. Hamilton, Division of Pathology and Laboratory Medicine, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 85, Houston, TX 77030. Phone: 713-792-2040; Fax: 713-792-4094; E-mail: shamilto{at}mdanderson.org.

Purpose: The epidemiology of colorectal carcinoma is well known to differ among countries but the molecular characteristics are usually assumed to be similar. International differences in molecular pathology have not been studied extensively but have implications for the management of patients in different countries and of immigrant patients.

Experimental Design: We evaluated the CpG island methylator phenotype pathway characterized by concordant methylation of gene promoters that often silences transcription of the genes, the microsatellite instability pathway, and K-ras and p53 gene status in 247 colorectal carcinomas from the three selected Middle Eastern countries of Egypt, Jordan, and Turkey.

Results: Colorectal carcinoma from Egypt had the lowest frequencies of methylation. In multinomial logistic regression analysis, Jordanian colorectal carcinoma more frequently had methylation involving the p16 tumor suppressor gene (odds ratio, 3.5; 95% confidence interval, 1.2-10.6; P = 0.023) and MINT31 locus (odds ratio, 2.3; 95% confidence interval, 1.0-5.1; P = 0.041). The K-ras proto-oncogene was more frequently mutated in colorectal carcinoma from Turkey (odds ratio, 2.9; 95% confidence interval, 1.2-6.7; P = 0.016), but p53 overexpression was more common in both Jordanian and Turkish colorectal carcinoma than in Egyptian cases (odds ratio, 2.5; 95% confidence interval, 1.2-5.5; P = 0.019; and odds ratio, 3.6; 95% confidence interval, 1.8-7.1; P = 0.0003, respectively). The findings in Turkish colorectal carcinoma were most similar to those reported for Western cases.

Conclusions: Colorectal carcinoma from Middle Eastern countries have differing gene methylation patterns and mutation frequencies that indicate dissimilar molecular pathogenesis, probably reflecting different environmental exposures. These molecular differences could affect prevention strategies, therapeutic efficacy, and transferability of clinical trial results.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2005 by the American Association for Cancer Research.